Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008

Table 1 Patients pre-ART and on-ART follow-up characteristics, CMSDS, Abidjan, Côte d’Ivoire, 2003-2008

Characteristics	N = 1008
At ART initiation
Sex, female, n (%)	673	(67)
Age (years), median (IQR)	35.0	(29.7-41.9)
CD4 count (cell/mm³), median (IQR)	186	(97–258)
WHO clinical stage 3 or 4, n (%)	136	(13)
BMI (kg/m²), median (IQR)	21.3	(19.1-23.9)
Patients on specific ART regimen, n (%)
2NRTIs + nevirapine ^α	562	(55.8)
2NRTIs + efavirenz ^β	332	(32.9)
2NRTIs + ritonavir boosted PI*	78	(7.7)
Others**	36	(3.6)
Hemoglobin (g/dl), median (IQR)	10.8	(9.4-12.1)
Patients with prior use of cotrimoxazole^†, n (%)	709	(70)
Follow-up on ART
Cumulative (PY)	2076
Median (IQR), in months	17.3	(5.7-38.0)
Death, n (%)	47	(4.6)
Patients lost to follow-up^‡, n (%)	128	(12.7)

IQR, Interquartile Range; WHO, World Health Organization; ART, Antiretroviral Therapy; BMI, Body Mass Index; d4T, Stavudine, 3TC, Lamivudine; AZT, zidovudine; ddI, Didanosine; TDF, Tenovofir diproxil fumarate; FTC, Emtricitabine; ABC, Abacavir.
α: d4T + 3TC (n = 484), AZT + 3TC (n = 78).
β: AZT + 3TC (n = 234), d4T + 3TC (n = 56), TDF + FTC (n = 38), d4T + ddI (n = 2), ddI + 3TC (n = 1), ABC + 3TC (n = 1).
*: AZT + 3TC (n = 25), TDF + FTC (n = 12), d4T + 3TC (n = 4), ddI + ABC (n = 4), ddI + 3TC (n = 1), ABC + 3TC (n = 1)] + lopinavir/ritonavir (n = 47); AZT + 3TC (n = 21), d4T + 3TC (n = 10)] + indinavir/ritonavir (n = 31).
**: 3NRTIs (n = 30) : TDF + FTC + AZT (n = 28), AZT + 3TC + ABC (n = 2); Non-boosted PIs (n = 6) : AZT + 3TC + indinavir (n = 3), AZT + 3TC + nelfinavir (n = 3).
†: Use of cotrimoxazole at least once prior to antiretroviral initiation.
‡: Lost to follow-up: patients whose last contact with the study center was prior to 31 Dec 2008, and who were not found to be deceased, alive, or transferred out up to August 31^st 2009.

ISSN: 1471-2334